A short video explaining the concept of DDR, the role of Homologous Recombination Repair (HRR) in DNA repair and the impact of BRCA1 and BRCA2 mutations. It explores PARP inhibitors as the proof of concept for targeting DDR, demonstrating how they work and their clinical benefit.

 

 

Dr Robert L. Coleman has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, Aravive, ArQuel, Cell Medica, Clovis, Geistlich Pharma, Genetech, GenMab, ImmunoGen, Janssen, Medscape, Merck, Mersana, MoreHealth, OncLive, OncoMed, Physicians Educational Resource, Takeda, Tesaro, TRM Oncology and United Therapeutics. 

Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Artios Pharma Ltd.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

podcast Video podcast
Oncology 
Metastatic TNBC cannot wait

Optimising 1st line TROP2 ADC decisions in metastatic triple-negative breast cancer

Experts
Prof. Giuseppe Curigliano, Prof. Javier Cortés
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Oct 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from AstraZeneca.
conference-update Conference update

Episode

3

of 3

episode
Oncology 
How are new data shaping the landscape in HER2-mutant NSCLC?

Insights from WCLC 2026

Experts
Dr Joshua Sabari
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2026

Educational programme supported by an Independent Educational Grant from Bayer.